Grandfield & Dodd’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,261
| Closed | -$244K | – | 203 |
|
|
2024
Q3 | $244K | Buy |
1,261
+62
| +5% | +$13K | 0.01% | 196 |
|
|
2024
Q2 | $278K | Hold |
1,199
| – | – | 0.02% | 177 |
|
|
2024
Q1 | $259K | Hold |
1,199
| – | – | 0.02% | 183 |
|
|
2023
Q4 | $310K | Hold |
1,199
| – | – | 0.02% | 163 |
|
|
2023
Q3 | $308K | Hold |
1,199
| – | – | 0.02% | 158 |
|
|
2023
Q2 | $342K | Sell |
1,199
-160
| -12% | -$47.6K | 0.02% | 155 |
|
|
2023
Q1 | $378K | Buy |
+1,359
| New | +$376K | 0.03% | 151 |
|
|
2021
Q4 | – | Sell |
-823
| Closed | -$230K | – | 208 |
|
|
2021
Q3 | $230K | Hold |
823
| – | – | 0.02% | 190 |
|
|
2021
Q2 | $280K | Hold |
823
| – | – | 0.02% | 172 |
|
|
2021
Q1 | $230K | Sell |
823
-138
| -14% | -$37.2K | 0.02% | 179 |
|
|
2020
Q4 | $240K | Hold |
961
| – | – | 0.02% | 173 |
|
|
2020
Q3 | $270K | Sell |
961
-4
| -0.4% | -$1.12K | 0.02% | 155 |
|
|
2020
Q2 | $260K | Sell |
965
-18
| -2% | -$5.41K | 0.03% | 152 |
|
|
2020
Q1 | $311K | Buy |
983
+22
| +2% | +$6.68K | 0.04% | 139 |
|
|
2019
Q4 | $285K | Hold |
961
| – | – | 0.03% | 155 |
|
|
2019
Q3 | $224K | Hold |
961
| – | – | 0.02% | 168 |
|
|
2019
Q2 | $225K | Sell |
961
-66
| -6% | -$15.2K | 0.02% | 168 |
|
|
2019
Q1 | $243K | Hold |
1,027
| – | – | 0.03% | 154 |
|
|
2018
Q4 | $309K | Hold |
1,027
| – | – | 0.04% | 143 |
|
|
2018
Q3 | $363K | Hold |
1,027
| – | – | 0.04% | 145 |
|
|
2018
Q2 | $298K | Sell |
1,027
-120
| -10% | -$33.7K | 0.03% | 153 |
|
|
2018
Q1 | $314K | Hold |
1,147
| – | – | 0.04% | 149 |
|
|
2017
Q4 | $365K | Hold |
1,147
| – | – | 0.04% | 147 |
|
|
2017
Q3 | $359K | Hold |
1,147
| – | – | 0.04% | 148 |
|
|
2017
Q2 | $311K | Hold |
1,147
| – | – | 0.04% | 158 |
|
|
2017
Q1 | $314K | Sell |
1,147
-400
| -26% | -$113K | 0.04% | 154 |
|
|
2016
Q4 | $439K | Hold |
1,547
| – | – | 0.06% | 131 |
|
|
2016
Q3 | $484K | Hold |
1,547
| – | – | 0.06% | 121 |
|
|
2016
Q2 | $374K | Hold |
1,547
| – | – | 0.05% | 133 |
|
|
2016
Q1 | $403K | Hold |
1,547
| – | – | 0.06% | 122 |
|
|
2015
Q4 | $474K | Sell |
1,547
-50
| -3% | -$14.4K | 0.07% | 110 |
|
|
2015
Q3 | $466K | Sell |
1,597
-40
| -2% | -$13.2K | 0.08% | 109 |
|
|
2015
Q2 | $661K | Sell |
1,637
-252
| -13% | -$101K | 0.1% | 97 |
|
|
2015
Q1 | $798K | Sell |
1,889
-70
| -4% | -$27.6K | 0.12% | 89 |
|
|
2014
Q4 | $665K | Sell |
1,959
-453
| -19% | -$147K | 0.1% | 94 |
|
|
2014
Q3 | $798K | Buy |
2,412
+8
| +0.3% | +$2.64K | 0.13% | 92 |
|
|
2014
Q2 | $758K | Sell |
2,404
-100
| -4% | -$30.1K | 0.11% | 105 |
|
|
2014
Q1 | $766K | Sell |
2,504
-100
| -4% | -$31.7K | 0.12% | 100 |
|
|
2013
Q4 | $728K | Hold |
2,604
| – | – | 0.12% | 100 |
|
|
2013
Q3 | $627K | Sell |
2,604
-100
| -4% | -$22.4K | 0.11% | 105 |
|
|
2013
Q2 | $582K | Buy |
+2,704
| New | +$578K | 0.11% | 109 |
|
Other funds holding BIIB
Grandfield & Dodd's BIIB Position: Q4 2024 in Review
Grandfield & Dodd sold out of Biogen (BIIB) in Q4 2024, closing a stake of 1,261 shares — an estimated $244K sold.
Grandfield & Dodd first reported a position in BIIB in Q2 2013 and held it in 41 quarters. The position peaked at $798K in Q1 2015. 875 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.
- Grandfield & Dodd reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
- Grandfield & Dodd sold 1,261 Biogen shares in Q4 2024, an estimated $244K.
- Grandfield & Dodd first reported a position in Biogen in Q2 2013 and held it in 41 quarters.
- Grandfield & Dodd's Biogen position peaked at $798K in Q1 2015.
- 875 funds tracked by Wall St. Rank held Biogen as of Q4 2024.
Based on Grandfield & Dodd's 13F filing for Q4 2024, filed 6 Feb 2025.